FULC Fulcrum Therapeutics
- 7.840
- +0.490+6.67%
Fulcrum Therapeutics News
Goldman Sachs Upgrades Fulcrum Therapeutics to Buy From Neutral, Price Target Is $15
Fulcrum Therapeutics (FULC) has an average rating of outperform and price targets ranging from $5 to $19, according to analysts polled by Capital IQ. Price: 7.80, Change: +0.45, Percent Change: +6.12
HC Wainwright & Co. : The Fulcrum Therapeutics (FULC.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $17.00.
HC Wainwright & Co. : The Fulcrum Therapeutics (FULC.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $17.00.
HC Wainwright & Co. Reiterates Buy on Fulcrum Therapeutics, Maintains $17 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates Fulcrum Therapeutics (NASDAQ:FULC) with a Buy and maintains $17 price target.
Buy Rating Affirmed for Fulcrum Therapeutics: Licensing Deal With Sanofi and Promising Phase 3 Study
Fulcrum Therapeutics Is Maintained at Outperform by Oppenheimer
Fulcrum Therapeutics Is Maintained at Outperform by Oppenheimer
Oppenheimer Maintains Outperform on Fulcrum Therapeutics, Lowers Price Target to $14
Oppenheimer analyst Matthew Biegler maintains Fulcrum Therapeutics with a Outperform and lowers the price target from $16 to $14.
Fulcrum Therapeutics Inc (FULC) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
Fulcrum Upgraded by Goldman Sachs Ahead of Phase 3 Data
INFN, VYGR and AMSC Are Among After Hour Movers
Fulcrum Therapeutics Raised to Buy From Neutral by Goldman Sachs
Fulcrum Therapeutics Raised to Buy From Neutral by Goldman Sachs
Goldman Sachs: Upgraded Fulcrum Therapeutics (FULC.US) rating from neutral to buy, with a target price of $15.00.
Goldman Sachs: Upgraded Fulcrum Therapeutics (FULC.US) rating from neutral to buy, with a target price of $15.00.
Goldman Sachs Upgrades Fulcrum Therapeutics to Buy, Announces $15 Price Target
Goldman Sachs analyst Corinne Jenkins upgrades Fulcrum Therapeutics from Neutral to Buy and announces $15 price target.
Fulcrum Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 89.87% Goldman Sachs → $15 Upgrades Neutral → Buy 03/13/2024 77.22% RBC Capital → $14 Initiates
Buy Rating Upheld for Fulcrum Therapeutics Amid Sanofi Partnership and Upcoming Trial Catalysts
Earnings Call Summary | Fulcrum Therapeutics(FULC.US) Q1 2024 Earnings Conference
The following is a summary of the Fulcrum Therapeutics, Inc. (FULC) Q1 2024 Earnings Call Transcript:Financial Performance:Fulcrum Therapeutics reported a net loss of $26.9 million for Q1 2024, compar
Sanofi Gains License for Ex-U.S. Rights to Fulcrum Muscular Dystrophy Candidate
Sanofi Signs License Deal for Rare Genetic Muscle Disease Drug
Sanofi (SAN.PA) on Monday said it entered into a license agreement with Fulcrum Therapeutics for losmapimod, a potential treatment of facioscapulohumeral muscular dystrophy, a rare genetic muscle diso
Fulcrum Therapeutics Q1 2024 Earnings: Misses Analyst Net Income Projections Amid Strategic ...
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersTevogen Bio Holdings (NASDAQ:TVGN) stock rose 55.4% to $1.53 during Monday's pre-market session. The market value of their outstanding shares is at $251.8 million. MiNK Therapeutics (NASDAQ:INK
Rising Fortunes: Fulcrum Therapeutics (FULC) Is Surging Pre-Market
Fulcrum Therapeutics Inc.'s (NASDAQ: FULC) shares are witnessing a remarkable ascent on the US market today, reflecting a surge of 13.39% during the pre-market session, with a trading value of $8.47. This surge is attributed to a significant collaboration unveiling. Forward-Moving Cooperation For the development and commercialization of losmapimod, Fulcrum Therapeutics (FULC) has recently marked ...
Analysis
Price Target
No Data
